DaVita Inc. filings document the operating results, governance and capital structure of a public kidney care and dialysis services company. Its 8-K reports furnish quarterly financial results, including revenue, operating income, per-share results, cash flow measures, treatment economics and share repurchase activity.
Proxy filings cover board matters, executive compensation, shareholder voting items and governance disclosures. Other current reports record material financing arrangements, amendments to secured credit facilities, share repurchase authorizations and the company's common stock listing on the New York Stock Exchange under DVA.
Form 144 notice: proposed sale of Common Stock related to DVA. The filing lists proposed sales tied to SAR exercises dated 11/17/2024 (1,400 shares) and 08/28/2024 (5,055 shares). The excerpt also records a sale by Kathleen Waters of 8,950 shares on 06/15/2026 for $1,860,202.07.
The filing identifies UBS Financial Services, Inc. at 11 Madison Ave as the broker-dealer line and shows a table entry with 6,455 in the securities column and a separate numeric entry of 64,200,000 shares tied to 06/15/2026. The document appears to be a routine Rule 144 notice of proposed sales rather than an operational or financial report.
DaVita Inc. entered into a Ninth Amendment to its 2019 Credit Agreement, adding an incremental $500 million in senior secured Tranche B-2 Term Loans maturing in May 2031. These loans are in U.S. dollars and bear interest at either a Base Rate plus a 75-basis-point applicable margin or Term SOFR plus a 175-basis-point applicable margin.
DaVita has used or will use the new term loan proceeds to repay a portion of its senior secured revolving loan facility terminating in November 2030, pay related fees and expenses, and for general corporate purposes. At its virtual 2026 annual meeting, stockholders representing 59,865,902 shares, about 91% of shares outstanding as of April 9, 2026, elected nine directors, ratified KPMG LLP as auditor for 2026, and approved named executive officer compensation on an advisory basis.
DaVita Inc. director Phyllis R. Yale reported a bona fide gift of 5,038 shares of DaVita common stock. The shares were transferred at no stated value per share. After this gift, she directly holds 9,525 shares, indicating she retains a meaningful ongoing equity stake in the company.
Pullin Dennis W reported acquisition or exercise transactions in this Form 4 filing.
DaVita Inc. director Dennis W. Pullin received a grant of 250 shares of Common Stock on May 15, 2026. The shares were awarded at no stated purchase price as equity compensation. After this award, he directly holds a total of 2,671 DaVita common shares.
Moore Gregory J. reported acquisition or exercise transactions in this Form 4 filing.
DaVita Inc. director Gregory J. Moore received 250 shares of common stock as a grant on May 15, 2026, at no cost. This compensation-related award increased his directly held stake to 7,813 shares. The transaction reflects an equity grant rather than an open-market purchase or sale.
Schoppert Wendy Lee reported acquisition or exercise transactions in this Form 4 filing.
DaVita Inc. director Wendy L. Schoppert reported a compensation-related stock grant and updated holdings. She received an award of 250 shares of DaVita common stock at $0.0000 per share, bringing her directly held common stock to 250 shares.
The filing also reports 3,637 shares of common stock held indirectly through the Wendy L. Schoppert Revocable Trust after the reported date. No open-market purchases or sales were reported in this filing.
Arway Pamela M reported acquisition or exercise transactions in this Form 4 filing.
DaVita Inc. director Pamela M. Arway reported receiving a grant of 250 shares of DaVita common stock on May 15, 2026. The shares were awarded at a stated price of $0.00 per share, indicating a compensation-related stock award rather than an open-market purchase.
Following this grant, Arway directly holds 26,945 shares of DaVita common stock. This filing reflects a small, routine equity award that modestly increases her direct ownership stake in the company.
DaVita Inc. director Phyllis R. Yale received 250 shares of Common Stock as a grant or award, with no cash price per share reported. This non-derivative acquisition increased her direct holdings to 14,563 DaVita shares, reflecting routine equity-based compensation rather than an open-market purchase.
DESOER BARBARA J reported acquisition or exercise transactions in this Form 4 filing.
DAVITA INC. director Barbara J. Desoer reported a compensation-related stock grant. She received 250 shares of Common Stock as a grant or award at a stated price of $0.00 per share, bringing her directly held position to 250 shares.
The filing also shows 13,771 shares of Common Stock held indirectly through the “Marc J. Desoer and Barbara J. Desoer 1998 Trust dated September 7, 1998,” reflecting additional beneficial ownership reported via a trust structure.
Schechter Adam H reported acquisition or exercise transactions in this Form 4 filing.
DaVita Inc. director Adam H. Schechter received a grant of 250 shares of DaVita common stock on May 15, 2026. The shares were awarded at a price of $0.00 per share, indicating a compensation-related equity award rather than a market purchase. Following this grant, Schechter directly holds 5,692 shares of DaVita common stock.